No Data
No Data
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $65
CervoMed Updates Investors on Business and Clinical Progress
Morgan Stanley Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $35
Morgan Stanley Sticks to Their Buy Rating for CervoMed (CRVO)
CervoMed: A Strong Buy on Pioneering DLB Treatment and Solid Financial Footing
Express News | CervoMed Inc: Believes to Fund Its Operating Expenses and Capital Expenditure Requirements Through 2025.
No Data
I Am 102927471 :![](https://emoticon.futunn.com/moomoo_winter_day/mw_14.png)